At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Skin (dermatologic) conditions are common in people who are receiving or have received cancer treatment. Sometimes the condition is related to the cancer, and sometimes it is related to cancer treatment. In either case, skin conditions can affect a person's quality of life.
- A Phase 1b/2 Study of Disitamab Vedotin With Tucatinib in People With Solid Tumors
Full Title A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination with Other Anticancer Therapies in Solid Tumors
Purpose
Researchers want to see if disitamab vedotin plus tucatinib is safe and works well in people with advanced solid tumors. They want to find the best dose of disitamab vedotin to give with tucatinib. The people in this study have different types of HER2-positive and HER2-low solid tumors, including breast cancer.
The HER2 protein plays a role in cancer growth and survival. When people have HER2-positive cancer, their cancer cells have high levels of HER2 on them. When people have HER2-low cancer, their cancer cells have low levels of HER2 on them.
Disitamab vedotin targets cells with HER2. By destroying these cells, disitamab vedotin may help slow or stop the growth of your cancer. Tucatinib blocks enzymes called tyrosine kinases that fuel cancer growth.
If you join this study, you will get both disitamab vedotin and tucatinib. Disitamab vedotin is given intravenously (by vein) and tucatinib is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have HER2-positive or HER2-low breast cancer or other solid tumor that has spread or cannot be removed with surgery.
- Have completed prior anti-cancer therapies at least 4 weeks before getting the study treatment.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Shanu Modi’s office at 646-888-4564.
Protocol
24-306Phase
Phase I/II (phases 1 and 2 combined)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06157892ClinicalTrials.gov
-
In this study, researchers are assessing the drug asciminib for people who recently learned they have chronic myeloid leukemia (CML). They will take it twice a day. If after two years they do not respond well to asciminib, they may take the drug nilotinib with asciminib.
-
Radiation therapy is one of the usual approaches to treating triple-negative breast cancer (TNBC). Researchers think that adding the immunotherapy drug pembrolizumab, with or without olaparib, to radiation therapy may be a better treatment for TNBC than radiation therapy alone.
-
Researchers are seeking the best dose of raludotatug deruxtecan (R-DXd) for people with ovarian cancer when given with standard chemotherapy. The people in this study have ovarian cancer that came back after chemotherapy that included a platinum-containing drug.
-
Acute lymphoblastic leukemia (ALL) in infants (babies under 1 year of age) can be challenging to treat. Researchers in this study are assessing the addition of 2 new drugs to standard chemotherapy for ALL in infants.
-
Researchers want to find the best dose of INCA033989 to use in people with myelofibrosis (MF) and essential thrombocytopenia (ET). These diseases are called myeloproliferative neoplasms. The people in this study have myeloproliferative neoplasms that came back or keep growing even after treatment. In addition, their cancers have a mutation (change or variant) in the CALR exon-9 gene.
-
In this study, researchers want to see if adding stereotactic body radiation therapy (SBRT) to standard drug therapy is effective for people with estrogen receptor (ER)-positive HER2-positive oligometastatic breast cancer that has gotten worse at one metastatic site despite medical treatment. Oligometastatic breast cancer is cancer that has spread to a small number of parts of the body. SBRT delivers extremely precise, very intense doses of radiation to cancer cells.
-
Researchers are comparing bone marrow transplantation to maintenance chemotherapy as post-induction treatment in older people with acute myeloid leukemia (AML) in remission. The people in this study are 65 or older and already had azacitidine and venetoclax as induction treatment. 
-
In this study, researchers want to find the best dose of RGT-61159 to treat salivary gland cancer. The people in this study have adenoid cystic carcinoma that came back or keeps growing after treatment.